Holen Sie sich die Stockscreener-App
7.14
0.97%
-0.07
Schlusskurs vom Vortag:
$7.21
Offen:
$7.17
24-Stunden-Volumen:
37,686
Relative Volume:
0.27
Marktkapitalisierung:
$88.42M
Einnahmen:
$4.28M
Nettoeinkommen (Verlust:
$-7.28M
KGV:
-8.765
EPS:
-0.8146
Netto-Cashflow:
$-6.17M
1W Leistung:
+1.13%
1M Leistung:
+5.00%
6M Leistung:
+46.91%
1J Leistung:
+196.27%
1-Tages-Spanne:
$7.10
$7.30
1-Wochen-Bereich:
$6.94
$7.47
52-Wochen-Spanne:
$2.1963
$9.33
Neuraxis Inc Stock (NRXS) Company Profile
Firmenname
Neuraxis Inc
Sektor
Branche
Telefon
(812) 689-0791
Adresse
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
7.14 | 88.42M | 4.28M | -7.28M | -6.17M | -0.8146 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuraxis Inc Aktie (NRXS) Neueste Nachrichten
Neuraxis, Inc. Files Form 8-K with SEC: Company Details, Address, and Stock Listing on NYSE American - Minichart
NeurAxis Declares Q2 Stock Dividend on Series B - TipRanks
Neuraxis declares stock dividend for Series B preferred, ~80,463 common shares to be issued - TradingView
NRXSNeuraxis Inc Latest SEC Filings - Finviz
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell 3000E Growth Benchmark - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell Microcap Index - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell 3000E Index - marketscreener.com
Price to sales forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Price to sales forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Enterprise value to EBIT forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Enterprise value to EBIT forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Price to book forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Enterprise value to revenue forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Price to earnings forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Enterprise value to EBITDA forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentProfit Inflection Point - dars.gov.et
NeurAxis, Inc. Actuals & Estimates (AMEX:NRXS) - TradingView
NRXS Forecast — Price Target — Prediction for 2027 - TradingView
Neuraxis Inc (NRXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neuraxis Inc (NRXS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neuraxis Inc (NRXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neuraxis Inc (NRXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuraxis Inc (NRXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuraxis Inc (NRXS) Institutional Confidence - TradingKey
Neuraxis Inc (NRXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuraxis Inc (NRXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuraxis Inc (NRXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuraxis Inc. (NRXS) Q1 2026 Earnings: Narrower Loss Surprises Market, Shares Drop 2.76%Balance Sheet Strength - dars.gov.et
NeurAxis Stockholders Approve Directors and Equity Compensation Plans - The Globe and Mail
Neuraxis elects board members and approves plan amendments at annual meeting - Investing.com
NRXS Q1 2026 Earnings: Smaller-than-Expected Loss Bolsters Investor SentimentShare Repurchase Impact - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates Amid Ongoing Development FocusGuidance Accuracy Score - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates but Stock Declines on Broader ConcernsRetail Earnings Report - dars.gov.et
NRXS Q1 2026 Earnings: EPS Beat Surprises as Pre-Revenue Biotech Tightens LossesEstimate Revision Count - The Legal Advocate
NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionForward EPS Estimate - thelegaladvocate.com
Neuraxis Inc. (NRXS) Slides 2.15% as Key Support Level TestedPCR Divergence - The Legal Advocate
NRXS: Record Q1 revenue and expanded coverage drive growth in pediatric and VA neuromodulation markets - TradingView
NRXS Q1 2026 Earnings: EPS Beats Estimates Despite Revenue AbsenceRevenue Warning Signal - The Legal Advocate
Neuraxis Inc. (NRXS) Q1 2026 Earnings: EPS Surpasses Estimates Amid Operational ProgressGAAP Earnings Report - The Legal Advocate
NRXS: Neuromodulation therapies for GI disorders drive growth with FDA clearance and strong clinical data - TradingView
Neuraxis Inc. (NRXS) Holds Near Support After Marginal DeclineMA Cross Alert - Newser
Neuraxis Inc. (NRXS) Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Slips on Pre‑Revenue Concerns - Newser
NeurAxis Earnings Call Highlights Growth and Hurdles - The Globe and Mail
NeurAxis (NRXS) Gains on Reimbursement Updates and Guideline MomentumShare Dilution Risk - The Legal Advocate
Minot Light Capital Fund Drops 2.7 Percent Amid Sector Rotation - HarianBasis.co
NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum - Insider Monkey
Neuraxis (NRXS) Stock Analysis: -5.84% Loss — Key Levels 2026-05-18Stock Idea Hub - Newser
NeurAxis slides 21%, raises $5M via stock - MSN
The surprise hidden in Neuraxis NRXS last earnings report Q4 2025 Earnings Beat EstimatesCrowd Verified Signals - Newser
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y - Yahoo Finance
Finanzdaten der Neuraxis Inc-Aktie (NRXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
Kapitalisierung:
|
Volumen (24h):